vimarsana.com

Page 46 - அமெரிக்கன் கலைக்கழகம் ஆஃப் நரம்பியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Former Senator and Vice President Walter Fritz Mondale, Dead at 93

Former Senator and Vice President Walter Fritz Mondale, Dead at 93
redstate.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from redstate.com Daily Mail and Mail on Sunday newspapers.

Former Vice President Walter Mondale Dead at 93

Former Vice President Walter Mondale Dead at 93
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

COVID Deaths Higher With Neuro Syndromes in Hospitalized Patients

email article Hospitalized COVID-19 patients with acute neurologic syndromes and signs had a much higher risk of death, the Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID) study showed. Mortality was nearly six times higher in hospitalized COVID-19 patients with clinically verified neurologic manifestations than in hospitalized COVID-19 patients with or without neurologic features (OR 5.99, 95% CI 4.33-8.28, P

Roche s Ocrevus shows significant benefit in early-stage MS patients

Roche’s Ocrevus shows significant benefit in early-stage MS patients The data was presented virtually at the American Academy of Neurology annual meeting New data for Roche’s Ocrevus has shown significant benefit in patients with early-stage relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS), the Swiss pharma announced last week. The data, presented virtually at the American Academy of Neurology (AAN) annual meeting, comes from the open label phase IIIb ENSEMBLE and a post-hoc analysis of the phase III ORATORIO studies. In the ENSEMBLE study, 85% of recently diagnosed RRMS patients treated with Ocrevus (ocrelizumab) achieved no evidence of disease activity (NEDA) after 48 weeks.

Biogen Inc : Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients

Biogen Inc.: Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients (nusinersen) Additional research reinforces the potential of biomarkers and highlights new digital tools that may help guide future treatment approaches and decisions for people with SMA CAMBRIDGE, Mass., April 19, 2021Inc. (Nasdaq: BIIB) today announced new data from the SPINRAZA (nusinersen) clinical development program aimed at optimizing outcomes for people with spinal muscular atrophy (SMA) and advancing understanding of the disease. These data are being presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting, April 17-22.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.